View Financial HealthCathay Biotech 配当と自社株買い配当金 基準チェック /26Cathay Biotech配当を支払う会社であり、現在の利回りは1.04%で、収益によって十分にカバーされています。主要情報1.0%配当利回り0.003%バイバック利回り総株主利回り1.0%将来の配当利回りn/a配当成長-6.9%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向55%最近の配当と自社株買いの更新お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Xiang Yang Wu was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025お知らせ • Jun 04Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai Chinaお知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025Reported Earnings • Oct 31Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 3Q 2023). Revenue: CN¥770.8m (up 44% from 3Q 2023). Net income: CN¥97.7m (up 36% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023).お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥46.38, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total loss to shareholders of 13% over the past year.お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024Cathay Biotech Inc. announced that they will report Q3, 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥38.08, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 31% over the past year.Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.30 in 2Q 2023). Revenue: CN¥759.8m (up 45% from 2Q 2023). Net income: CN¥142.2m (down 23% from 2Q 2023). Profit margin: 19% (down from 35% in 2Q 2023). The decrease in margin was driven by higher expenses.お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024Cathay Biotech Inc. announced that they will report first half, 2024 results on Aug 31, 2024お知らせ • Jun 06Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai ChinaReported Earnings • May 01First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.10 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.10 in 1Q 2023). Revenue: CN¥684.5m (up 35% from 1Q 2023). Net income: CN¥105.3m (up 83% from 1Q 2023). Profit margin: 15% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥49.16, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 32x in the Chemicals industry in China. Total loss to shareholders of 7.2% over the past year.New Risk • Apr 09New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report Q1, 2024 results on Apr 30, 2024Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.95 in FY 2022)Full year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥367.0m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • Dec 29Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report fiscal year 2023 results on Apr 30, 2024Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.25 in 3Q 2022). Revenue: CN¥535.1m (down 2.5% from 3Q 2022). Net income: CN¥72.0m (down 52% from 3Q 2022). Profit margin: 14% (down from 27% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Chemicals industry in China.お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥525.0m (down 16% from 2Q 2022). Net income: CN¥184.4m (up 14% from 2Q 2022). Profit margin: 35% (up from 26% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023Cathay Biotech Inc. announced that they will report first half, 2023 results on Aug 16, 2023お知らせ • Jun 27Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group LimitedCathay Biotech Inc. announced a private placement of common shares for gross proceeds up to CNY 6,600 million on June 25, 2023. The transaction will include participation from new investor China Merchants Group Limited. The transaction is subject to the approval of shareholders of the company.Reported Earnings • Apr 26Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)Full year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥553.3m (down 9.0% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses.Board Change • Mar 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.決済の安定と成長配当データの取得安定した配当: 688065は 10 年未満配当金を支払っており、この間、支払額は 変動性 が高かった。増加する配当: 688065は5年間のみ配当金を支払っており、それ以降は支払額が減少しています。配当利回り対市場Cathay Biotech 配当利回り対市場688065 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (688065)1.0%市場下位25% (CN)0.4%市場トップ25% (CN)1.9%業界平均 (Chemicals)1.2%アナリスト予想 (688065) (最長3年)n/a注目すべき配当: 688065の配当金 ( 1.04% ) はCN市場の配当金支払者の下位 25% ( 0.37% ) よりも高くなっています。高配当: 688065の配当金 ( 1.04% ) はCN市場の配当金支払者の上位 25% ( 1.93% ) と比較すると低いです。株主への利益配当収益カバレッジ: 688065の配当金は、合理的な 配当性向 ( 54.6% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: 688065は配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YCN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 12:24終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cathay Biotech Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Junjun ZhuHaitong International Research LimitedTing Zhou ZhuangHuatai Research
お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.
お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Xiang Yang Wu was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026
お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026
お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025
お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025
お知らせ • Jun 04Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai China
お知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025
お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025
Reported Earnings • Oct 31Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 3Q 2023). Revenue: CN¥770.8m (up 44% from 3Q 2023). Net income: CN¥97.7m (up 36% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023).
お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥46.38, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total loss to shareholders of 13% over the past year.
お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024Cathay Biotech Inc. announced that they will report Q3, 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥38.08, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 31% over the past year.
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.30 in 2Q 2023). Revenue: CN¥759.8m (up 45% from 2Q 2023). Net income: CN¥142.2m (down 23% from 2Q 2023). Profit margin: 19% (down from 35% in 2Q 2023). The decrease in margin was driven by higher expenses.
お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024Cathay Biotech Inc. announced that they will report first half, 2024 results on Aug 31, 2024
お知らせ • Jun 06Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai China
Reported Earnings • May 01First quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.10 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.10 in 1Q 2023). Revenue: CN¥684.5m (up 35% from 1Q 2023). Net income: CN¥105.3m (up 83% from 1Q 2023). Profit margin: 15% (up from 11% in 1Q 2023). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥49.16, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 32x in the Chemicals industry in China. Total loss to shareholders of 7.2% over the past year.
New Risk • Apr 09New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report Q1, 2024 results on Apr 30, 2024
Reported Earnings • Feb 24Full year 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.95 in FY 2022)Full year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥367.0m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • Dec 29Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report fiscal year 2023 results on Apr 30, 2024
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.25 in 3Q 2022). Revenue: CN¥535.1m (down 2.5% from 3Q 2022). Net income: CN¥72.0m (down 52% from 3Q 2022). Profit margin: 14% (down from 27% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Chemicals industry in China.
お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.
Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥525.0m (down 16% from 2Q 2022). Net income: CN¥184.4m (up 14% from 2Q 2022). Profit margin: 35% (up from 26% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023Cathay Biotech Inc. announced that they will report first half, 2023 results on Aug 16, 2023
お知らせ • Jun 27Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group LimitedCathay Biotech Inc. announced a private placement of common shares for gross proceeds up to CNY 6,600 million on June 25, 2023. The transaction will include participation from new investor China Merchants Group Limited. The transaction is subject to the approval of shareholders of the company.
Reported Earnings • Apr 26Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)Full year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥553.3m (down 9.0% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses.
Board Change • Mar 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.